Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Tariff Resilience Score: 0/10 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603229 Zhejiang Ausun Pharmaceutical Co Ltd SHSE:603229
78 GF Score
Price ¥7.31
GF Value ¥10.33
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Zhejiang Ausun Pharmaceutical Co Tariff Resilience Score?

Zhejiang Ausun Pharmaceutical Co has the Tariff Resilience Score of 0, which implies that the company might have .

Zhejiang Ausun Pharmaceutical Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Zhejiang Ausun Pharmaceutical Co might have .

Zhejiang Ausun Pharmaceutical Co  (SHSE:603229) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Zhejiang Ausun Pharmaceutical Co Tariff Resilience Score Related Terms

SHSE:603229
78GF Score
Zhejiang Ausun Pharmaceutical Co Ltd SHSE:603229
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥7.31 is trading 29.2% below its estimated GF Value™ of ¥10.33. GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603229:

  • Tariff Resilience Score: 0
  • GF Value™: ¥10.33 vs. price of ¥7.31 (29.2% below fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Ausun Pharmaceutical Co Business Description

Address No.5, Donghai 4th Avenue, chemical raw materials base Linhai Park East, Zhejiang Province, Taizhou, CHN, 317016
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
78GF Score

Get the complete analysis for SHSE:603229

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.31
Price
¥10.33
GF Value